These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10991851)

  • 1. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM; Grau O; Charron A; Renaudin H; Gruson D; Bébéar C
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
    Bébéar CM; Renaudin H; Charron A; Bové JM; Bébéar C; Renaudin J
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2304-11. PubMed ID: 9736554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.
    Bebear CM; Renaudin J; Charron A; Renaudin H; de Barbeyrac B; Schaeverbeke T; Bebear C
    Antimicrob Agents Chemother; 1999 Apr; 43(4):954-6. PubMed ID: 10103208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].
    Gushchin AE; Ladygina VG; Govorun VM
    Mol Gen Mikrobiol Virusol; 1999; (4):19-24. PubMed ID: 10621934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.
    Bébéar CM; Charron A; Bové JM; Bébéar C; Renaudin J
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2024-31. PubMed ID: 9687401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones.
    Bebear CM; Bové JM; Bebear C; Renaudin J
    Antimicrob Agents Chemother; 1997 Feb; 41(2):269-73. PubMed ID: 9021178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of regions determining resistence to fluoroquinolones in genes gyrA and parC in clinical isolates of Mycoplasma hominis].
    Gushchin AE; Ladygina VG; Govorun VM; Taraskina AM; Savicheva AM
    Mol Gen Mikrobiol Virusol; 2000; (4):33-5. PubMed ID: 11186458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.
    Kenny GE; Young PA; Cartwright FD; Sjöström KE; Huang WM
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2493-6. PubMed ID: 10508030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
    Ito H; Yoshida H; Bogaki-Shonai M; Niga T; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2014-23. PubMed ID: 7811012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Tankovic J; Perichon B; Duval J; Courvalin P
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.